Immunic (IMUX) shares rose more than 14% in premarket trading after it reported "positive" outcomes from an interim analysis of its phase 3 trial of vidofludimus calcium for the treatment of relapsing multiple sclerosis.

Based on the interim analysis, an independent data monitoring committee has recommended that the trials should continue as planned. Completion is expected in 2026.

The trial includes two identical multicenter, randomized, double-blind phase 3 trials enrolling about 1,050 each designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in relapsing multiple sclerosis patients.

The primary endpoint for both trials is time to first relapse in up to 72 weeks. Secondary endpoints include time to worsening of disability.

Price: 1.8000, Change: +0.25, Percent Change: +16.13